Marshall Wace, LLP Atai Life Sciences N.V. Transaction History

Marshall Wace, LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.5 - $2.19 $26,925 - $39,310	17,950 Added 2.31%	793,839 $1.56 Million
Q4 2023 Feb 14, 2024	BUY	$1.04 - $1.55 $806,924 - $1.2 Million	775,889 New	775,889 $1.09 Million
Q3 2022 Nov 14, 2022	BUY	$3.14 - $4.87 $137,949 - $213,953	43,933 New	43,933 $147,000
Q1 2022 May 16, 2022	SELL	$4.66 - $7.66 $1.89 Million - $3.11 Million	-406,618 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$6.82 - $17.8 $2.77 Million - $7.24 Million	406,618 New	406,618 $3.1 Million

12.4M

77.8K

50.3K

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $197M
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.